Showing results (2481-2490 of 2,828) with videos related to

Sort By:
Pageof 283
Physical Review Letters|May 22, 2026
Experimental Observation of Anomalous Stopping of Mega-ampere Electron Current in Porous MaterialsK Jiang, Z G Deng, T W Huang, et al.
The Pharmacogenomics Journal|May 28, 2014
Pharmacogenomic diversity in Singaporean populations and EuropeansL R Brunham, S L Chan, R Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trialT B Powles, M S Van der Heijden, Y Loriot, et al.
Nature Biomedical Engineering|October 16, 2021
Wirelessly operated bioelectronic sutures for the monitoring of deep surgical woundsViveka Kalidasan, Xin Yang, Ze Xiong, et al.
Nature|September 3, 2025
Amygdala-liver signalling orchestrates glycaemic responses to stressJ R E Carty, K Devarakonda, R M O'Connor, et al.
European Journal of Human Genetics : EJHG|April 30, 2015
Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP arraySantiago Rodriguez, Tom R Gaunt, Yiran Guo, et al.
Science (New York, N.Y.)|August 7, 2004
Surficial deposits at Gusev Crater along Spirit Rover traversesJ A Grant, R Arvidson, J F Bell, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.
Genes and Immunity|August 21, 2015
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to femalesR C Chiaroni-Clarke, Y R Li, J E Munro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
Pageof 283